NICE To Hear Appeals On Alzheimer’s Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. National Institute for Health & Clinical Excellence will hear five appeals against a final appraisal determination that limits recommended National Health Service coverage of four Alzheimer's disease treatments
You may also be interested in...
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.